🔗 Visit the ClinicalTrials.gov page for NCT00610857
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. | J Clin Oncol | 2011 | 1.24 |
| 2 | Cancer immunotherapy in clinical practice -- the past, present, and future. | Chin J Cancer | 2014 | 0.98 |
| 3 | Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma. | Expert Opin Pharmacother | 2011 | 0.80 |
| 4 | Tremelimumab. | Drugs R D | 2010 | 0.75 |